Eric Bouffet1, Michael Capra, Ute Bartels. 1. Paediatric Neuro-Oncology Program, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G1X8, Canada. eric.bouffet@sickkids.ca
Abstract
INTRODUCTION: Chemotherapy has limited role in the up-front management of ependymoma. At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience. METHODS: The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma. DISCUSSION: The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.
INTRODUCTION: Chemotherapy has limited role in the up-front management of ependymoma. At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience. METHODS: The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma. DISCUSSION: The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.
Authors: ZoAnn E Dreyer; Richard P Kadota; Clinton F Stewart; Henry S Friedman; Donald H Mahoney; Larry E Kun; Charles W McCluggage; Peter C Burger; James Kepner; Richard L Heideman Journal: Neuro Oncol Date: 2003-10 Impact factor: 12.300
Authors: Maryam Fouladi; Fred Laningham; Jianrong Wu; Melinda A O'Shaughnessy; Kristen Molina; Alberto Broniscer; Sheri L Spunt; Inga Luckett; Clinton F Stewart; Peter J Houghton; Richard J Gilbertson; Wayne L Furman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Mariko DeWire; Maryam Fouladi; David C Turner; Cynthia Wetmore; Cynthia Hawkins; Carmen Jacobs; Ying Yuan; Diane Liu; Stewart Goldman; Paul Fisher; Michael Rytting; Eric Bouffet; Yasmin Khakoo; Eugene I Hwang; Nicholas Foreman; Clinton F Stewart; Mark R Gilbert; Richard Gilbertson; Amar Gajjar Journal: J Neurooncol Date: 2015-04-10 Impact factor: 4.130
Authors: Martin Benesch; Martin Mynarek; Hendrik Witt; Monika Warmuth-Metz; Torsten Pietsch; Brigitte Bison; Stefan M Pfister; Kristian W Pajtler; Marcel Kool; Ulrich Schüller; Klaus Pietschmann; Björn-Ole Juhnke; Stephan Tippelt; Gudrun Fleischhack; Irene Schmid; Christof M Kramm; Peter Vorwerk; Andreas Beilken; Carl Friedrich Classen; Pablo Hernáiz Driever; Gabriele Kropshofer; Thomas Imschweiler; Andreas Lemmer; Rolf-Dieter Kortmann; Stefan Rutkowski; Katja von Hoff Journal: Oncologist Date: 2019-03-08
Authors: Yuan Y Thompson; Vijay Ramaswamy; Phedias Diamandis; Craig Daniels; Michael D Taylor Journal: Childs Nerv Syst Date: 2015-09-09 Impact factor: 1.475
Authors: Lindsey M Hoffman; S Reed Plimpton; Nicholas K Foreman; Nicholas V Stence; Todd C Hankinson; Michael H Handler; Molly S Hemenway; Rajeev Vibhakar; Arthur K Liu Journal: J Neurooncol Date: 2014-01 Impact factor: 4.130
Authors: Sridharan Gururangan; Jason Fangusaro; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Amar Gajjar; Stewart Goldman; Henry S Friedman; Roger J Packer; James M Boyett; Larry E Kun; Roger McLendon Journal: Neuro Oncol Date: 2012-09-26 Impact factor: 12.300
Authors: Karen D Wright; Vinay M Daryani; David C Turner; Arzu Onar-Thomas; Nidal Boulos; Brent A Orr; Richard J Gilbertson; Clinton F Stewart; Amar Gajjar Journal: Neuro Oncol Date: 2015-11-04 Impact factor: 12.300